Mersana Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
By linking drugs to a proprietary nanometer-scale polymer, Mersana Therapeutics can favorably affect properties of chemotherapeutic agents such as solubility, half-life, and accumulation in tumor tissue, thereby widening their therapeutic window.
You may also be interested in...
Mersana Moves Into Antibody-Drug Conjugates With Endo Collaboration
Previously partnered with Teva on a small molecule drug conjugate, biotech says its focus going forward will be on developing ADCs, with partners and in-house.
In Oncology Drug Boom, Can Next-Gen Cytotoxics Fit In?
The drug industry has placed a bull's eye on the field of oncology as a key therapeutic area, but not all oncology players are created equal.
Mersana Teams With Teva To Develop Polymer Conjugate Cancer Drug
Linking fumagillin analogue with polymer should prevent CNS toxicities seen with previous fumagillin candidates.